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Highlights 
 
• CDK4 promotes glycolysis and inhibits fatty acid oxidation  
 
• CDK4 inhibits AMPK activity through direct phosphorylation of the AMPK- α2 
subunit. 
 
• CDK4-/- mice have AMPK-dependent increased oxidative metabolism 
 
 
 
eTOC Blurb 
 
Lopez-Mejia et al. show in this study that CDK4, a protein that is usually involved in the 
control of cell division, is an important regulator of the energy balance of the cell 
through the direct inhibition of the activity of AMPK, which is a major regulator of 
energy consuming processes.  
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Abstract 
 
 The roles of CDK4 in the cell cycle have been extensively studied, however 
less is known about the mechanisms underlying the metabolic regulation by CDK4. 
Here, we report that CDK4 promotes anaerobic glycolysis and represses fatty acid 
oxidation in mouse embryonic fibroblasts (MEFs) by targeting the AMP-activated 
protein kinase (AMPK). We also show that fatty acid oxidation (FAO) is specifically 
induced by AMPK complexes containing the α2 subunit. Moreover, we report that 
CDK4 represses FAO through direct phosphorylation and inhibition of AMPKα2. 
The expression of non-phosphorylatable AMPKα2 mutants, or the use of a CDK4 
inhibitor, both increased FAO rates in MEFs and myotubes. In addition, Cdk4-/- 
mice have increased oxidative metabolism and exercise capacity. Inhibition of 
CDK4 mimicked these alterations in normal mice, but not when skeletal muscle 
was AMPK-deficient. This novel mechanism explains how CDK4 promotes 
anabolism by blocking catabolic processes (FAO) that are activated by AMPK.  
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Introduction 
 
  Promitotic signals such as growth factors increase the levels of D-type 
cyclins (cyclin D1, D2 and D3), which bind and activate CDK4/6 to trigger the 
phosphorylation of the retinoblastoma-associated protein pRB and other pocket 
proteins, i.e. p107 and p130 (Malumbres and Barbacid, 2005). Rb phosphorylation 
enables release of the E2F transcription factors that promote the transcription of 
genes necessary for the replication of the genome (Malumbres and Barbacid, 
2005). The role of CDK4 in the regulation of cell cycle progression has been 
extensively studied in eumetazoan organisms, and alterations in CDK4 activity 
have been associated with cancer development and progression (Malumbres and 
Barbacid, 2001, 2009; O'Leary et al., 2016). For example, the R24C mutation, which 
is used in this study, renders CDK4 resistant to inhibition by INK4 inhibitors and 
has been reported to confer a genetic predisposition to melanoma (Rane et al., 
2002; Rane et al., 1999; Wolfel et al., 1995).  
 Cell division requires substantial amounts of ATP, and numerous metabolic 
intermediates to support biosynthesis of essential molecules, such as lipids and 
nucleic acids. Proliferating cells preferentially use anaerobic glycolysis to generate 
large amounts of ATP, and to provide metabolic intermediates to support cell 
growth (Jones and Thompson, 2009). Growing evidence demonstrates that 
regulatory crosstalk exists between metabolic pathways and regulators of cell cycle 
progression. Mitochondrial respiration and metabolism are coordinated with cell 
cycle progression by cell cycle regulators (Lopez-Mejia and Fajas, 2015; Salazar-
Roa and Malumbres, 2016)). Our laboratory and others have demonstrated that 
CDK4 is one such “metabolic” cell cycle regulator (Blanchet et al., 2011; Icreverzi et 
al., 2012; Lagarrigue et al., 2016; Lee et al., 2014). Indeed, we have previously 
shown that CDK4 regulates oxidative metabolism via the E2F1 transcription factor, 
in muscle and brown adipose tissue (Blanchet et al., 2011) and promotes the 
insulin-signaling pathway in mature adipocytes (Lagarrigue et al., 2016). Overall, 
the participation of cell cycle regulators in the control of energy homeostasis 
occurs mainly through the activation of anabolic processes (Aguilar and Fajas, 
2010). The AMP-activated protein kinase (AMPK) is a central inhibitor of such 
anabolic processes and might therefore be repressed by cell-cycle regulators. 
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Under conditions of low cellular energy, AMP and ADP are increased relative to 
ATP, and this is sensed by AMPK. AMPK exists as heterotrimeric complexes 
composed of a catalytic subunit, α, and two regulatory subunits, β and γ; the α and 
β subunits exist as two isoforms (α1/α2 and β1/β2, encoded by the PRKAA1/2 and 
PRKAB1/2 genes), and the γ subunit as three isoforms (γ1/γ2/γ3, encoded by 
PRKAG1/2/3), thus generating up to 12 combinations of heterotrimeric complex 
(Carling, 2004; Grahame Hardie, 2016; Hardie et al., 2012; Ross et al., 2016b). 
AMPK is regulated both by phosphorylation/dephosphorylation and by the 
relative cellular concentrations of adenine nucleotides, with the two mechanisms 
being intimately linked. Firstly, the upstream kinases LKB1 (liver kinase B1) 
(Hawley et al., 2003; Shaw et al., 2004; Woods et al., 2003) or CaMKK2 
(calmodulin-dependent kinase kinase-2/-β) (Hawley et al., 2005; Hurley et al., 
2005; Woods et al., 2005) activate AMPK through the phosphorylation of Thr172 of 
the α subunit (Hawley et al., 1996). Secondly, AMPK is regulated through the 
competitive binding of ATP, or AMP and ADP at up to three sites on the γ subunit. 
When cellular energy levels are low, binding of AMP or ADP enhances Thr172 
phosphorylation by LKB1 and inhibits Thr172 dephosphorylation by protein 
phosphatases, while binding of AMP (but not ADP) causes further allosteric 
activation (Ross et al., 2016a). Metabolic stresses that reduce intracellular ATP 
concentrations are therefore the best-characterized activators of AMPK, although 
it has recently been shown that glucose deprivation can activate AMPK by an 
adenine nucleotide-independent mechanism (Zhang et al., 2017). Once activated, 
AMPK promotes catabolic pathways that generate ATP (e.g. fatty acid oxidation, 
FAO) while switching off anabolic pathways and other ATP-requiring processes to 
restore cellular ATP levels (Carling, 2004; Grahame Hardie, 2016; Hardie et al., 
2012; Ross et al., 2016b).  
 Other kinase activities that are induced by growth stimuli are known to 
inhibit AMPK. This includes AKT a key effector of the insulin/IGF1-signaling 
pathway that antagonizes the AMPK pathway through phosphorylation of AMPKα1 
on Ser487 (Horman et al., 2006b), or ERK, that was shown to phosphorylate the 
same residue (Lopez-Cotarelo et al., 2015). The cyclic AMP-dependent protein 
kinase (PKA) also phosphorylates and negatively regulates AMPK (Djouder et al., 
2010; Hurley et al., 2006), and Thr481 and Ser477 on AMPKα1 are phosphorylated 
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by glycogen synthase kinase 3 (GSK3)(Suzuki et al., 2013), following a “priming” 
phosphorylation of Ser487 by AKT.  
 
Muscle function requires a finely tuned balance between anabolism and 
catabolism in order to respond to physiological challenges within the available 
energy supply. AMPK is a major coordinator of energy intake and utilization in 
exercising muscle (Hoffman et al., 2015), functioning to enhance energy 
availability. Amongst other effects, AMPK promotes FAO to maintain ATP cellular 
stores, although the exact role of AMPK in regulation of muscle FAO has been 
controversial (Mounier et al., 2015).  
  
 In this study, we sought to determine whether CDK4 participates in energy 
homeostasis by inhibiting catabolic processes. The mechanisms by which the 
activity of AMPK is inhibited under anabolic conditions, such as during cell cycle 
progression or in resting muscle, have not been thoroughly studied.  We report 
here that CDK4 enhances anaerobic glycolysis and represses fatty acid oxidation. 
Surprisingly, the AMPKα1 and α2 subunits play distinct roles. We provide here a 
molecular mechanism whereby CDK4-CycD3 complexes directly repress α2-
containing complexes to inhibit FAO. We show that chemical and genetic inhibition 
of CDK4 also promotes oxidative metabolism in vivo, as evidenced by decreased 
respiratory exchange ratio (RER) and increased exercise performance in mice 
lacking CDK4 activity.  
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Results 
CDK4 modulates FAO in an E2F1-independent manner  
 We previously demonstrated that CDK4 is a major mediator of insulin 
signaling, and therefore contributes to the positive regulation of biosynthetic 
processes, such as fatty acid synthesis, and the inhibition of catabolic pathways, 
such as lipolysis (Lagarrigue et al., 2016). To further investigate the contribution of 
CDK4 to metabolic regulation, Seahorse analyses were performed. Cdk4R24C/R24C 
mouse embryonic fibroblasts (MEFs), which express a hyperactive CDK4 mutant, 
exhibited a significant increase in anaerobic glycolysis, as measured by the 
extracellular acidification rate (ECAR), whereas Cdk4-/- MEFs had impaired 
anaerobic glycolysis (Figures 1a-b). In contrast, CDK4 activity was inversely 
correlated with FAO. Cdk4R24C/R24C MEFs metabolized palmitate at a low rate, 
whereas Cdk4-/- MEFs showed increased palmitate oxidation (Figures 1c-d). 
Interestingly, the effects of CDK4 on substrate use were independent of E2F1 
activity, since deletion of E2F1 in Cdk4R24C/R24C MEFs failed to reverse the effects of 
Cdk4R24C on anaerobic glycolysis or palmitate oxidation (Figures 1e-h). These 
results suggest that CDK4 controls substrate utilization in MEFs independently of 
E2F1.  
 
CDK4 regulation of FAO is AMPK-dependent 
 The decrease in FAO observed in response to constitutive activation of 
CDK4 is opposite to the effect seen with AMPK activation (Fullerton et al., 2013; 
Hardie, 2015; Hardie and Pan, 2002; O'Neill et al., 2014). Therefore, we analyzed 
the involvement of AMPK in the CDK4-mediated regulation of FAO in MEFs. Basal 
levels of phosphorylated ACC (pACC), which is a known target and marker of 
AMPK activity, were decreased in Cdk4R24C/R24C MEFs but increased 3-fold in the 
Cdk4-/- cells (Figures 2a-b and S1a-b), suggesting that CDK4 antagonizes AMPK 
function. Moreover, the activation of AMPK by the specific activator A769662 
(Goransson et al., 2007; Moreno et al., 2008) was reduced in Cdk4R24C/R24C MEFs 
(Figures 2a-b), suggesting that CDK4 can prevent AMPK activation. In addition, 
increased AMP/ATP and ADP/ATP ratios were observed in MEFs expressing the 
hyperactive CDK4 mutant, which suggested a lower catabolic rate (Figures 2c-d). 
Interestingly, in Cdk4-/- MEFs, comparable pACC levels were measured both in the 
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basal state and upon AMPK stimulation (Figures 2a-b). This finding implies that in 
the absence of CDK4, AMPK reaches its activated state without need for any 
further stimulation. Likewise in Cdk4-/- cells, and in WT MEFs treated with 
A769662, we observed a significant decrease of AMP/ATP and ADP/ATP ratios 
(Figures 2 c-f). 
Next, we studied the physiological relevance of the increase in AMPK 
activity in Cdk4-/- cells, using FAO assays in MEFs treated with A769662 and with 
the non-selective AMPK inhibitor Compound C. As expected, the levels of palmitate 
oxidation in WT MEFs were at least 25% higher in A769662-treated cells (Figures 
2g and S1c-d). However, Cdk4-/- cells did not respond in the same assay to A769662 
treatment. By contrast, AMPK activation by A769662 in Cdk4R24C/R24C MEFs was 
only able to restore WT levels of FAO (Figures 2g and S1c-d). AMPK inhibition in 
Cdk4-/- cells (albeit by the non-selective inhibitor compound C) produced 
consistent results. The levels of pACC in CDK4 null MEFs, as well as the increased 
FAO levels were restored back to basal levels (Figures S1e-g). Taken together, 
these results suggest that CDK4 inhibits the AMPK pathway. 
 
The AMPKα2 subunit is required for efficient FAO in MEFs 
 Our results suggested that CDK4 has a negative effect on FAO via the 
regulation of AMPK activity, raising the question of which AMPK subunits 
contribute to this effect. Interestingly, the deletion of either AMPKα subunit in 
MEFs resulted in increased ECAR, indicating increased glycolysis, whereas the 
complete abrogation of AMPK activity had no effect, perhaps due to disruption of 
glucose transport into the cells (Figures 3a-b). However, although AMPKα1KO 
MEFs metabolized palmitate as efficiently as control cells, both AMPKα2KO and 
AMPK α1/ α2KO (DKO) cells exhibited significantly reduced levels of FAO (Figures 
3c-d). Consistently, A769662 failed to trigger FAO in cells lacking the α2 subunit 
(both α2KO and DKO). Thus, despite being more abundant in MEFs (Morizane et 
al., 2011), the AMPKα1 subunit cannot substitute for the α2 subunit in the control 
of FAO, even when allosterically activated by A769662 (Figures 3e-f and S1h-i). In 
addition, ACC phosphorylation could be detected upon stimulation with A769662 
in both AMPK α1KO and AMPK α2KO MEFs (Figure S1j), suggesting that both 
AMPK subunits can phosphorylate ACC1 and therefore inhibit lipid synthesis, but 
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only AMPKα2 can promote FAO. Taken together, these results suggest that AMPK 
complexes containing α2 specifically control FAO. 
 
CDK4 phosphorylates the AMPK α2 subunit  
 The inhibition of AMPKα2-dependent FAO could be the result of a direct 
phosphorylation by CDK4. In vitro kinase assays showed that recombinant 
CDK4/CycD3 phosphorylated all GST fusions of AMPK subunits tested at different 
levels (Figure 4a, loading control in S2a). Interestingly, AMPKα2 and AMPKγ2 
were phosphorylated by CDK4 to a greater extent than pRB, which is the canonical 
CDK4 substrate (Figure 4b). Since the specificity of CDKs is partially determined by 
substrate docking on the cyclin subunit, kinase assays were also performed using 
recombinant CDK4/CycD1 instead of CDK4/CycD3. The phosphorylation of the 
AMPK subunits was very low under these conditions (Figure S2b), suggesting that 
AMPK phosphorylation by CDK4 requires recognition by cyclin D3. 
 AMPKα2 was predicted to contain 6 CDK4 phosphorylation sites (Thr85, 
Ser176, Ser345, Ser377, Thr485, Ser529). Out of these six potential sites, five were listed 
in the phosphoNET database (Figure 4c). Site-directed mutagenesis (S>A or T>A) 
combined with protein truncation studies (Figure S3c) identified Ser345, Ser377, 
Thr485 and Ser529 as CDK4 phosphorylation sites (Figures 4d-e, loading control in 
S3d). Phosphorylation by CDK4 was completely abrogated in a full-length 
recombinant protein carrying Ser to Ala or Thr to Ala mutations at the four CDK4 
phosphosites (α2 S>A mutant), suggesting that the four newly-identified residues 
account for all sites phosphorylated on GST-AMPKα2 by CDK4 in cell-free assays 
(Figure 4f-g, loading control in S2e). The phosphorylation of Ser377 and Thr485 have 
been previously described in proteomic studies (Figure S2f) (Dinkel et al., 2011; 
Gnad et al., 2011; Hornbeck et al., 2015)), including cell cycle-related 
phosphoproteomes (Daub et al., 2008; Kettenbach et al., 2011), and in liver upon 
insulin stimulation (Humphrey et al., 2015), suggesting that the regulation of 
AMPK by CDK4 is important for cell cycle progression and for the insulin signaling 
pathway. Moreover, we found the four newly identified CDK4 phosphosites to be 
conserved among the AMPKα2 subunits of several mammalian species (Figure 
S3a) but not between the AMPKα1 and AMPKα2 isoforms (Figure S3b).  
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In intact cells, AMPK is found as a heterotrimeric complex; therefore 
recombinant kinase-inactive α2β2γ1 complexes were also used as substrate for 
recombinant CDK4/CycD3 complexes. After mass spectrometry analysis we 
obtained 83 % coverage of the AMPKα2 subunit and observed the phosphorylation 
in Ser176 and Ser377 (Figure 4h). A targeted analysis to increase coverage showed 
phosphorylation of Thr485 and Ser529 with low detectability. The phosphorylation 
of Ser345 and Ser377 was also detected in myotubes and muscle tissue, which 
express high levels of the α2 subunit (Figures S4a-b and table S1). Interestingly, 
our results suggest that these phosphorylations are present when AMPK is inactive 
since the activating Thr172 phosphorylation was not found in 5 out of 6 
experiments (Figures S4a-b). Taken together, these data indicate that the α2 
subunit of AMPK is a substrate for CDK4-CycD3 complexes in cell-free assays, and 
that some of these phosphorylations occur in vivo, in conditions in which CDK4 is 
active (Blanchet et al., 2011; Lagarrigue et al., 2016), but AMPK is inactive.  
 
AMPKα2 phosphorylation is necessary and sufficient for FAO repression by 
CDK4 
 To elucidate the functional relevance of the phosphorylation of AMPKα2 by 
CDK4, we compared the regulatory activities of AMPKα2 S>A, AMPKα2 and 
AMPKα1 in the context of FAO. Transfection of AMPK DKO MEFs with the AMPKα2 
S>A mutant conferred ACC phosphorylation levels that where higher than those 
observed in AMPKα1- or α2-transfected cells both in the basal state and upon 
stimulation by A769662 (Figure 5a). Similarly, ectopic expression of the AMPKα2 
S>A mutant in the FAO-defective AMPK DKO MEFs rescued palmitate oxidation to 
a greater extent than that which was observed upon transfection with WT 
AMPKα2 (Figures 5b and S5a). Taken together, these results indicate that defective 
targeting of AMPKα2 by CDK4 at Ser345, Ser377, Thr485 and Ser529 results in 
increased AMPKα2 FAO-promoting activity. 
 In order to demonstrate that CDK4 represses FAO by repressing AMPK 
activity, wild type and AMPK mutant cells were treated with CDK4 inhibitors. 
Inhibition of CDK4 activity by LY2835219 significantly increased FAO, after 24 
hours (Figures 5c and S5b) or 2 hours (Figures S5c-d) of treatment. Strikingly, the 
CDK4 inhibitor failed to increase FAO in both AMPK α2KO or AMPK DKO cells but 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10
not in AMPK α1KO cells, demonstrating that CDK4 targets AMPKα2 to alter cellular 
metabolism (Figures 5c, S5b and S5e-g). The overall positive effect of CDK4 
inhibition on AMPK activity was confirmed by analyzing ACC phosphorylation. 
Indeed, LY2835219 treatment induced a dose-dependent increase in the 
phosphorylation of ACC (Figures S5h and S5i). This effect correlated with 
decreased CDK4 activity given that phosphorylation of RB Ser780 was also reduced 
(Figures S5i). Of note, increased ACC phosphorylation and increased FAO could be 
detected after 2h of CDK4 inhibition, whereas inhibition of RB phosphorylation 
required longer treatments. Moreover, LY2835219 had a comparable effect as 
A769662, significantly decreasing AMP/ATP and ADP/ATP ratios in WT MEFs 
(Figures 2e-f and 5d-e). The use of LY2835219 suggests that DK4 inhibition 
promotes catabolic processes in an AMPKα2-subunit dependent manner.  
We next decided to validate our finding in a more physiological cellular 
model. LY2835219 treatment induced an increase in FAO in C2C12 myotubes, 
which are known to express high levels of AMPKα2 (Figures S6a-b). In this model, 
CDK4 inhibition correlated with a dose-dependent increase of the phosphorylation 
of ACC, without significant increase of AMPK Thr172 phosphorylation (Figures S6c-
e). The direct involvement of AMPKα2 was confirmed by analyzing myotubes 
lacking AMPKα2 or both the α1 and α2 subunits (Lantier et al., 2010). Like in MEFs, 
FAO was impaired in the α2KO and DKO myotubes. Similarly, the CDK4 inhibitor 
failed to increase FAO in α2KO and DKO myotubes (Figures 5f and S6f).  Rescue of 
AMPK DKO myotubes with the AMPKα2 S>A mutant triggered ACC 
phosphorylation levels that where higher than those observed in AMPK α2-
transfected cells both in the basal state or upon stimulation with A769662 (Figure 
5g). Similarly, ectopic expression of the AMPKα2 S>A mutant in the FAO-defective 
AMPK DKO myotubes rescued palmitate oxidation to levels similar to those of WT 
myotubes (Figures 5h and S6g). Taken together, these results in muscle cells 
confirm that CDK4 modulates FAO through the specific inhibition of AMPKα2 
activity, and that a non-phosphorylatable AMPKα2 mutant has a FAO-promoting 
activity.  
 
 
CDK4 modulates oxidative metabolism and exercise capacity in vivo  
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We next investigated the contribution of CDK4 to oxidative metabolism and 
muscle function in vivo. Isolated mitochondria from Cdk4-/- muscles showed 
increased oxygen consumption, suggesting increased fatty acid oxidation capacity 
(Figures 6a-b). Increased FAO was further demonstrated by using intact muscle 
fibers from Flexor digitorum brevis (FDB) muscle (Figure 6c). Fibers from Cdk4-/-  
FDB muscle metabolized palmitate at a higher rate (Figure 6c-d) and were capable 
to reach  a higher maximal respiration (Figure 6c and 6e). The increased capacity 
of the muscles of Cdk4-/- mice to oxidize fatty acids suggested an overall metabolic 
phenotype in these mice.  
Cdk4-/- mice have decreased body weight (Figure 6f). onsistent with 
increased AMPK activity, Cdk4-/- mice exhibit increased exercise capacity and 
decreased RER, indicating a preference towards fat oxidation (Figures 6g-i). An 8-
day treatment with LY2835219 did not trigger significant alterations in body 
weight, and food intake (Figures 6j and S7d), although it induced a consistent 
albeit non-significant decrease in fat mass (Figure S7c) and a modest but 
significant increase in exercise performance (Figure 6k). A decrease in RER was 
observed after 4-5 days of treatment (Figure 6l-m). In vivo, the inhibition of CDK4 
triggered an increase in the phosphorylation of ACC in quadriceps muscle (Figures 
S7e and S7g), suggesting increased AMPK activity. This was accompanied by an 
increase of the slow-twitch fiber marker MyHC I (Figure S7i). MyHC I mRNA levels 
were also increased in gastrocnemius and tibialis muscles from LY2835219 
treated animals (Figures S7h-j). Overall, these data suggest that CDK4 is a negative 
regulator of exercise capacity and whole body oxidative metabolism in mice.  
 
CDK4 regulation of oxidative metabolism and exercise capacity in vivo 
requires muscle AMPK 
To determine if the effects of CDK4 inhibition in exercise performance and 
whole body oxidative metabolism require muscle AMPK, we treated muscle-
specific AMPK α1/α2 KO mice (MDKO) (Lantier et al., 2014) with the CDK4 
inhibitor. Consistently, treatment with LY2835219 did not trigger significant 
alterations in body weight, or food intake (Figures 7a and S7m) in control nor in 
AMPK MDKO animals. In control animals, LY2835219 was sufficient to trigger a 
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decrease in fat mass (albeit not significant, p=0.1243), a modest increase in 
exercise performance and a decrease in RER (Figures 7b-d and S7l). In agreement 
with previous reports (Lantier et al., 2014; O'Neill et al., 2011), AMPK MDKO 
animals showed decreased RER and decreased exercise capacity (Figures 7b-d). 
However, they were not affected by the treatment with LY2835219 under our 
experimental conditions (Figures 7a-d and S7k-m). Taken together, these results 
show that the negative effects of CDK4 in oxidative metabolism and exercise 
performance in vivo involve muscle AMPK activity.  
 
Discussion  
 The contribution of CDK4 to the control of cell cycle progression, via pocket 
proteins and E2F transcription factors, has been extensively studied (Malumbres, 
2014) for more than two decades. However, only recently the CDK4/6-pRB/E2F1 
pathway was implicated in metabolic regulation (Aguilar and Fajas, 2010; Blanchet 
et al., 2011; Denechaud et al., 2016; Lagarrigue et al., 2016; Lee et al., 2014; Lopez-
Mejia and Fajas, 2015; Petrov et al., 2016; Salazar-Roa and Malumbres, 2016). Our 
study provides now evidence that the cell cycle kinase CDK4 is a key player in the 
control of cellular energy homeostasis, and can also act independently of E2F1 to 
regulate metabolic pathways.   
 Three major findings are described here. First, we found that CDK4 
negatively regulates the AMPK pathway and, thus, inhibits FAO through 
phosphorylation of the AMPKα2 subunit. Indeed, Cdk4-/- MEFs behaved like cells 
treated with an AMPK activator and exhibited high FAO levels and low levels of 
anaerobic glycolysis. Consistently, Cdk4R24C/R24C cells exhibited increased anaerobic 
glycolysis and very low FAO levels. A similar phenotype was observed in AMPK 
α2KO MEFs. Therefore, CDK4 activity is inversely correlated with AMPKα2-
dependent activity. These findings indicate that CDK4 plays a central role in 
mitochondrial FAO that involves AMPKα2 inhibition and is independent of other 
downstream effectors, such as E2F1. 
 Cell division requires high cellular energy levels. Despite the recent 
evidence that underscore the existence of a crosstalk between cell cycle regulators 
and energy metabolism (Lopez-Mejia and Fajas, 2015; Salazar-Roa and Malumbres, 
2016); the molecular mechanisms coupling energy production and cell cycle 
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progression remain to be elucidated. Based on our results, we propose that, to 
exert its role in both cell cycle progression and the insulin signaling pathway, 
CDK4 represses catabolism by directly targeting at least one of the catalytic 
subunits of AMPK, namely the α2 subunit. Interestingly, AKT, another key player of 
the insulin signaling pathway, phosphorylates the α1 subunit of AMPK, thus 
reducing α1 Thr172 phosphorylation and the subsequent activation of the AMPK 
heterotrimer (Hawley et al., 2014; Horman et al., 2006a). Remarkably, previous 
evidence from our laboratory demonstrates that CDK4 is a key effector of the AKT 
pathway (Lagarrigue et al., 2016). Surprisingly, GSK3 has been reported to inhibit 
AMPK activity, after phosphorylation of the α subunit by AKT(Suzuki et al., 2013). 
This finding is somehow unexpected since GSK3 activity is negatively regulated via 
phosphorylation by AKT, upon insulin stimulation. Moreover, GSK3 is known to 
inhibit rather than promote anabolic pathways, like the synthesis of glycogen 
(Cohen and Frame, 2001). 
 The second major finding in our study is the observation that the function of 
AMPK heterotrimers can differ depending on their α subunit isoform. Rather few 
studies have focused on the specific function of each AMPK subunit (although see a 
recent review (Ross et al., 2016b)), and models completely lacking AMPK activity  
are often used to study the function of AMPK. Liver-specific deletion or 
overexpression of the AMPKα2 subunit suggested that this isoform is involved in 
regulating the balance between lipid synthesis and FAO (Andreelli et al., 2006; 
Foretz et al., 2005), but these studies did not assess the differences in specificity 
between α1 and α2. Interestingly, leptin was shown to directly trigger FAO in 
muscle (Minokoshi et al., 2002), and to trigger an anorexigenic response in 
hypothalamus (Minokoshi et al., 2004), in an AMPKα2-dependent manner. The 
effect on food intake may be triggered through AKT signaling via phosphorylation 
of AMPKα2 by p70S6K (Dagon et al., 2012). Other positive energy balance signals 
can also reduce food intake via AMPKα2 activity in the brain (Claret et al., 2007; 
Kim et al., 2004). The isoform-specific roles of AMPK isoforms in whole body 
energy homeostasis were further highlighted by the fact that the AMPKα2 subunit 
is essential for nicotine-triggered lipolysis in adipocytes (Wu et al., 2015). 
However, the specific regulation of energy homeostasis by AMPKα2, and the 
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molecular mechanisms regulating α2-isoform specific AMPK activity have 
remained largely unknown. 
The third major finding in our study is that the modulation of CDK4 
activity in vivo can result in modifications in whole body energy homeostasis and 
exercise performance. These modifications require the expression of AMPK in 
skeletal muscle. Our results are in agreement with previous studies demonstrating 
that the use of AICAR can increase exercise performance in sedentary mice while 
increasing the proportion of slow twitch fibers (Narkar et al., 2008).  However, the 
exact mechanisms that mediate this phenotype remain to be studied. Global 
approaches to determine muscle reprograming at the proteomics and gene 
expression level will allow further study of the involvement of DK4 in muscle 
biology, and most particularly in exercise. Given that muscle expresses the 
AMPKα2 subunit highly, and responds to exercise by down-regulating CDK activity 
(Hoffman et al., 2015), we believe that the study of CDK4-AMPKα2 interaction in 
skeletal muscle will be highly relevant to the discovery of pharmacological 
interventions to promote or enhance the beneficial effects of exercise on general 
health.  
By identifying 4 new specific CDK4 phosphosites in the α2 subunit of 
AMPK, we have discovered a specific role for this subunit in the control of fatty 
acid metabolism, which we could not demonstrate for the α1 subunit.  
Interestingly, we detected the phosphorylation of two of these residues, Ser377 and 
Ser 345, in muscle samples from resting mice and in myotubes stimulated with 
insulin or IGF1.  
 FAO repression by CDK4 emerges as an additional level of metabolic 
regulation by this kinase, which also mediates other effects of the insulin signaling 
pathway (Lagarrigue et al., 2016), including lipid synthesis, glycolysis (Denechaud 
et al., 2016) and proliferation (Malumbres and Barbacid, 2005).    
 In conclusion, our results demonstrate that CDK4 is a major regulator of 
cellular energy homeostasis. By combining experimental data from cellular 
metabolism analyses, biochemistry and molecular biology studies and in vivo 
experiments, our work provides insights into the complex regulation of anabolic 
and catabolic pathways. These novel findings can have broad implications, not only 
in the regulation of cell metabolism during proliferation, but also in the control of 
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energy utilization at the level of the whole organism.  Moreover, they highlight the 
need to delve deeper into the specific functions of the different AMPK 
heterotrimers, as well as in the regulation of AMPK inactivation.   
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FIGURE LEGENDS 
 
Figure 1. CDK4 modulates FAO in an E2F1-independent manner  
Cdk4+/+, Cdk4-/- and Cdk4R24C/R24C MEFs were submitted to a glycolysis assay, during 
which ECAR was measured at the basal level and upon glucose injection (a), or to a 
FAO assay, in which the palmitate induced OCR was measured (in % OCR 
compared to the basal OCR) (c). The glycolytic rate was calculated in (b). The area 
under curve of the palmitate induced OCR was quantified in (d).  
E2f1+/+, E2f1-/-, Cdk4R24C/R24C E2f1+/+ and Cdk4R24C/R24C E2f1-/- MEFs were submitted 
to a glycolysis assay, during which ECAR was measured at the basal level and upon 
glucose injection (e), or to a FAO assay, in which the palmitate induced OCR was 
measured (in % OCR compared to the basal OCR) (g). The glycolytic rate was 
calculated in (f). The area under curve of the palmitate induced OCR was 
quantified in (h).  
Data were expressed as mean ± s.e.m.  
 
Figure 2. CDK4 regulation of FAO is AMPK-dependent 
Cdk4+/+, Cdk4-/- and Cdk4R24C/R24C MEFs were starved for 3 hours and then 
stimulated with 50µM A769662, the western blot analysis shows the A769662 
induced ACC phosphorylation in Cdk4+/+, Cdk4-/- and Cdk4R24C/R24C cells (a).  The 
pACC levels were quantified in (b).  SV40 immortalized cells were placed in KHB 
medium containing 1.5mM carnitine and 300µM Oleate for AMP, ADP and ATP 
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quantification by HPLC. The AMP/ATP and ADP/ATP ratios are shown in (c) and 
(d). The AMP/ATP and ADP/ATP ratios of WT SV40 immortalized cells treated 
with 50µM A769662 for 8 hours are shown in (e) and (f). Cdk4+/+, Cdk4-/- and 
Cdk4R24C/R24C MEFs were treated with DMSO or 50µM A769662 for 2 hours in KHB 
medium and submitted to a FAO assay in which the palmitate induced OCR was 
measured (in % OCR compared to the basal OCR). The area under curve of the 
palmitate induced OCR was quantified in (g).  
Data were expressed as mean ± s.e.m. See also Figure S1. 
 
Figure 3.  The AMPKα2 subunit is required for efficient fatty acid oxidation in 
MEFs 
AMPK WT, AMPK A1 KO, AMPK A2 KO and AMPK DKO SV40-immortalized MEFs 
were submitted to a glycolysis assay, during which ECAR was measured at the 
basal level and upon glucose injection (a), or to a FAO assay, in which the palmitate 
induced OCR was measured (in % OCR compared to the basal OCR) (c). The 
glycolytic rate was calculated in (b). The area under curve of the palmitate induced 
OCR was quantified in (d).  
AMPK WT and AMPK A2 KO SV40-immortalized MEFs were treated for 2 hours 
with DMSO or 50µM A769662 for 2 hours in KHB medium and submitted to a FAO 
assay in which the palmitate induced OCR was measured (in % OCR compared to 
the basal OCR) (e). The area under curve of the palmitate induced OCR was 
quantified in (f).  
Data were expressed as mean ± s.e.m. See also Figure S2. 
 
 Figure 4. CDK4 phosphorylates the AMPKα2 subunit  
(a) Cyclin D3-CDK4 directly phosphorylates full-length GST-AMPK subunits in vitro 
(n=3). Asterisks mark the proteins of interest.  The Phosphorylation score (in % of 
RB phosphorylation) was determined in (b). CDK consensus sites in human 
AMPKα2 (PRKAA2) are depicted in (c). (d) In vitro phosphorylation of WT and 
mutated (Ser or Thr to Ala) GST-AMPK α2 fragments (D1: 1-245 aa, D2: 246-356 
aa, D3: 357-422 aa, D4: 432-522 and D2-3: 246-422 aa, 1100-1321aa) by Cyclin 
D3/CDK4 (n=3). The Phosphorylation score (in % of the WT fragment) was 
determined in (e).  (f) In vitro phosphorylation of full-length WT GST-AMPKα2 and 
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full-length S>A GST-AMPKα2 by Cyclin D3/CDK4 (n=3). The Phosphorylation score 
(in % of RB phosphorylation) was determined in (g).  Kinase dead AMPK α2β2γ1 
trimers were used as a substrate for Cyclin D3-CDK4 complex and analyzed by 
mass spectrometry. A graphical overview of the sequence coverage of AMPKα2 
human protein in samples displayed by MsViz is depicted in (h). The thickness of 
the green bars is a function of the number of spectra matching the sequence 
region, while modification sites are labeled and shown as circles with size 
proportional to the number of spectra matching a given position. 
A truncated form of RB (hRB 379-928aa) was used as a positive control. A 
representative autoradiography for each kinase assay is shown.  
See also Figure S3. 
Figure 5.  AMPKα2 phosphorylation is necessary and sufficient for FAO 
repression by CDK4 
AMPK DKO SV40-immortalized MEFs were electroporated with plasmids encoding 
Myc-tagged AMPK A1, Myc-tagged AMPK A2 and Myc-tagged AMPK A2 S>A. 48h 
after, MEFs were starved for 3 hours, and treated for 2 hours with DMSO or 50µM 
A769662 before protein extraction, the western blot analysis shows the A769662 
induced ACC phosphorylation in transfected cells  (a).  
Electroporated MEFs were submitted to a FAO assay 48h after transfection, in 
which the palmitate induced OCR was measured (in % OCR compared to the basal 
OCR). The area under curve of the palmitate induced OCR was quantified in (b).  
AMPK WT and AMPK DKO SV40-immortalized MEFs were treated with DMSO or 
LY2835219 1,5µM for 24h, and submitted to a FAO assay, in which the palmitate 
induced OCR was measured (in % OCR compared to the basal OCR). The area 
under curve of the palmitate induced OCR was quantified in (c).  
AMPK WT SV40 immortalized cells were treated for 8h with DMSO or LY2835219 
1,5µM. AMP, ADP and ATP were quantified by HPLC. The AMP/ATP and ADP/ATP 
ratios are shown in (d) and (e). 
AMPK DKO myotubes were transfected with plasmids encoding Myc-tagged AMPK 
A2 and Myc-tagged AMPK A2 S>A. B. 48h after, myotubes were treated for 2 hours 
with DMSO or 50µM A769662 before protein extraction, the western blot analysis 
shows the A769662 induced ACC phosphorylation in transfected cells (g). 
Transfected myotubes were submitted to a FAO assay in which the palmitate 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24
induced OCR was measured (in % OCR compared to the basal OCR). The area 
under curve of the palmitate induced OCR was quantified in (h).  
Data were expressed as mean ± s.e.m. See also Figure S4 and S5. 
 
Figure 6. CDK4 modulates oxidative metabolism and exercise capacity in vivo  
Mitochondria isolated from gastrocnemius (a) and quadriceps (b) muscle from 
Cdk4+/+ and Cdk4-/- mice were submitted to a respiration assay using fatty acids as 
a substrate.  Isolated FDB muscle fibers from Cdk4+/+ and Cdk4-/- mice were 
submitted to a FAO assay in which the palmitate induced OCR was measured (in % 
OCR compared to the basal OCR) (c). The area under curve of the palmitate 
induced OCR is shown in (d). The maximal respiration was induced by FCCP and is 
shown in (e). 
Body weight of 25-30 weeks old male Cdk4+/+ and Cdk4-/- mice was measured in (f). 
Cdk4+/+ and Cdk4-/- were submitted to an exercise capacity testing on treadmill. The 
time before exhaustion was recorded in (g). RER of the aforementioned mice is 
depicted in (h) and (i).  
30-week-old wild type mice were gavaged with 37mg/kg of LY2835219 or vehicle 
for 8 days. Body weight (j) and exercise capacity (k) were measured the day after 
the last treatment. RER of the aforementioned mice after 5 days of treatment is 
depicted in (l) and (m).  
Data were expressed as mean ± s.e.m. See also Figure S6. 
 
Figure 7. CDK4 regulation of oxidative metabolism and exercise capacity in 
vivo requires muscle AMPK 
Body weight of 12-16 weeks old AMPK WT and AMPK MDKO females gavaged with 
37mg/kg of LY2835219 or vehicle for 8 days was measured in (a). Exercise 
capacity testing on treadmill. The time before exhaustion was recorded in (b). RER 
of the aforementioned mice is depicted in (c) and (d).  
Data were expressed as mean ± s.e.m. See also Figure S7. 
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STAR Methods 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be 
directed to and will fulfilled by Lluis Fajas (lluis.fajas@unil.ch) 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Cell culture 
MEFs were derived from embryos that were dissected 13.5 days after vaginal 
plugs. The Cdk4-/- (Cdk4nc), Cdk4R24C/R24C and E2f1-/- mice have been previously 
described(Denechaud et al., 2016; Lagarrigue et al., 2016).   
Prkaa1-/-, Prkaa2-/- individual KOs; and Prkaa1-/-; Prkaa2-/- double KO SV40 
immortalized MEF cells were prepared as described (Laderoute et al., 2006). They 
are referred in the manuscript as AMPK α1KO, AMPK α2KO and AMPK DKO.   
MEFs were cultured in DMEM/F12 supplemented with 10% fetal bovine serum 
(FBS, PAA Laboratories), glutamax (1mM), sodium pyruvate (1mM), non-essential 
amino-acids, 2-Mercapto-ethanol (50µM) and antibiotics in 5% CO2 37°C 
incubator. 
C2C12 myoblasts were obtained from ATCC and were cultured in low-glucose 
DMEM with 10% FBS in 5% CO2 37°C incubator. For myotube differentiation, when 
the cells reached 80-90% confluency, the culture medium was switched to DMEM 
containing 2% horse serum. The medium was changed every 2 days until day 5 to 
7 of differentiation.  
Primary myoblasts were grown in collagen coated plates cultured DMEM/F12 
supplemented with 20% fetal bovine serum, 2mM Glutamine and FGF (5ng/ml) in 
5% CO2 37°C incubator. For myotube differentiation, cells were plated on matrigel-
coated plates when the cells reached 80-90% confluency, the culture medium was 
switched to DMEM/F12 supplemented with 2% horse serum and 2mM Glutamine. 
The medium was changed every 2 days until day 4-5 of differentiation.  For rescue 
experiments, myotubes were transfected using lipofectamine 3000 (Thermo 
Fisher Scientific), at day 1 and day 3 of differentiation. The cells were assayed 48 
hours after the 2nd round of transfection.  
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Primary Cdk4+/+, Cdk4-/- and Cdk4R24C/R24C MEFs, as well as primary E2f1+/+, E2f1-/-, 
Cdk4R24C/R24C E2f1+/+ and Cdk4R24C/R24C E2f1-/- MEFs, between P2 and P5, were used 
for figures 1 and 2. SV40 immortalized MEFs were used for all other figures.    
Animal studies 
The generation of Cdk4-/-, that lack CDK4 in all tissues except pancreatic beta cells 
and were referred as Cdk4nc/nc in our previous study, was described in (Lagarrigue 
et al., 2016). Male mice were used.  
For gavage experiments, C57BL/6J male mice were obtained from Janvier Labs. 
Animals were gavaged daily with 37mg/kg of LY2835219 or vehicle for 8 days. 
Mice were acclimated and submitted to indirect calorimetry between day 4 and 
day 6.  Exercise capacity testing was performed the day after the last gavage. Body 
weight was controlled daily. Food intake was measured in the metabolic cages.  
To obtain skeletal muscle AMPK-deficient mice [AMPK_1fl/fl _2fl/fl human skeletal 
actin (HSA)-Cre_ mice on a C57Bl6- 129Sv mixed background], AMPK_1fl/fl_2fl/fl 
mice were interbred with transgenic mice expressing Cre recombinase under the 
control of the HSA promoter.  Female mice were used.  
The mice were housed in a facility on a 12-h light-dark cycle with free access to 
standard rodent chow and water.  
Mice were familiarized to the motorized rodent treadmill (Columbus Instruments, 
Columbus OH) on the J-2 and J-1 before the evaluation of exercise capacity. 
Familiarization consisted of an initial 10 min period where the treadmill speed and 
incline were set to zero with a slight electric shock grid at the back of the carpet set 
to 20 V, 0.34 mA, and 2 Hz. The treadmill speed was then increased steadily to 10 
m/min (J-2) and 12 m/min (J-1) for an additional 10 min. 
The day immediately following familiarization to the treadmill, mice were 
subjected to an exercise capacity test. For this, the mice were acclimated to the 
treadmill for 10 min, with the speed and incline set initially to zero. The treadmill 
speed was then increase to 8.5 m/min with an angle of inclination set to 0° for 9 
min. Next, the treadmill speed and incline was increased to 10 m/min and 5°, 
respectively, for 3 min. The speed was then increased by 2.5 m/min every 3 min to 
a maximum speed of 40 m/min, while inclination was increased by 5° every 9 min 
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until a maximum incline of 15°. 
Strict a priori criteria for exercise-induced exhaustion consisted in: (1) 10 
consecutive seconds on the electric grid; (2) spending more than 50% of time on 
the grid; and/or (3) lack of motivation to manual prodding. Mice were immediately 
removed from their respective lane once one or more of these criteria were 
reached.  
Following the protocol, mice were killed by cervical dislocation and skeletal 
muscles were isolated for analysis.  
All animal care and treatment procedures were performed in accordance with 
Swiss guidelines and were approved by the Canton of Vaud, Service de la 
Consommation et des Affaires Vétérinaires (SCAV) (authorization VD 3121.a). 
 
METHOD DETAILS 
Materials 
All cell culture reagents were purchased from GIBCO (Thermo Fisher Scientific). 
All chemicals, except if stated otherwise, were purchased from Sigma-Aldrich. The 
CDK4 inhibitor (LY2835219) and Compound C. were purchased from MedChem 
Express. Experiments were done using 1µM of LY2835219, unless stated 
otherwise. The AMPK allosteric activator was purchased from Abcam or MedChem 
Express. Unless stated otherwise, A769662 was used at a concentration of 50µM. 
γ33P-ATP was purchased from Perkin Elmer.  
Immunoblot 
For western blot analysis, the cells were seeded in 6-well plates 48 hours before 
the experiment, serum starved for 3 hours, and treated with either LY2835219 or 
A769662 for 2 hours.  
Total proteins extracts were subjected to SDS-PAGE analysis and transferred to 
nitrocellulose membranes for immunoblotting. The following antibodies were 
obtained from Cell Signaling Technology : ACC (no. 3662), phosphorylated ACC 
(ser79) (no. 3661), AMPK (no.2532), phosphorylated AMPK (Thr172) (no 2535), 
Myc-tag (no. 2276), phosphorylated RB (Ser780) (no. 8180). The following 
antibodies were obtained from Santa Cruz Technology: Cdk4 (C-22; sc-260), Rb (C-
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2; sc-74562), AMPK α2 (sc-19131). A second Myc-tag antibody was used to 
analyse myotube samples (abcam ab9106) 
 The α Tubulin (no. T6199) antibody was obtained from Sigma Aldrich, the actin 
(sc-1615) was obtained from Santa Cruz Technology.  
The levels of total proteins and the levels of phosphorylation of proteins were 
analyzed on separate gels. The band intensities on developed films, fusion FX 
images or chemidoc images or were quantified using Fiji image processing package 
(Schindelin et al., 2012). 
Plasmid constructs and mutagenesis 
pDONR223-hPRKAA1 (ref:23871), pDONR223-hPRKAA2 (ref:23671), pDONR223-
hPRKAB1 (ref:23360), pDONR223-hPRKAB2 (ref:23647), pDONR223-hPRKAG1 
(ref:23718), pDONR223-hPRKAG2 (ref:23689), pDONR223-hPRKAG3 (ref:23549) 
were provided from Addgene. The different GST subunits of human AMPK were 
obtained using the pDEST pGEX-2T vector of Gateway Cloning Technology 
(Invitrogen) starting from previously described pDONR223AMPK constructs. The 
different serine-to-alanine mutants of GST-hPRKAA2 were generated using a 
Quick-Change Site-Directed Mutagenesis kit (Stratagene) with the following 
primers (Supplemental Table 2). A similar strategy was used to obtain the 
truncated versions of GST-hPRKAA2 and the different serine-to-alanine mutants 
using the following primers (Supplemental Table 2).  
The Myc-hPRKAA1, the Myc-hPRKAA2 and the Myc-hPRKAA2-S345A-S377A-
T485A-S529A were obtained using the pDEST pCDNA3 MYC vector previously and 
the above described pDONR223-human AMPK constructs. pDONR-hRB 379-928aa 
was subcloned from pCMV human RB and generated using the pDONR221 vector 
of Gateway Cloning Technology. The pGEX-2T hRB 379-928aa was obtained using 
the pDEST pGEX-2T from Gateway Cloning Technology. 
GST production 
Independent AMPK subunits were cloned in the pDEST pGEX-2T and expressed in 
BL21 bacteria. GST-purified proteins were re-suspended in 50mM Tris.HCl [pH 8], 
100 mM NaCl, 5 mM DTT and 20% glycerol buffer. 
CDK4 Kinase assay 
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Kinase assays were performed using Independent AMPK subunits proteins and 
500ng of recombinant RB protein (Santa Cruz) as a substrate in kinase buffer (25 
mM Tris.HCl [pH 7.5], 150 mM NaCl, 10 mM MgCl2, 1 mM DTT, 5 mM Na4P2O7, 50 
mM NaF, 1 mM vanadate and protease inhibitor cocktail) with 40 μM ATP and 8 
μCi γ33PATP (Perkin Elmer) for 30 min at 30°C. Recombinant CDK4/cyclin D3 
kinase and CDK4/Cyclin D1 (ProQinase) were used. RB was used as a positive 
control.  
Boiling the samples for 5 min in the presence of denaturing sample buffer stopped 
the reaction. Samples were subsequently subjected to SDS–PAGE, and transferred 
to a nitrocellulose membrane before being exposed to an X-ray film at -80°C during 
4 hours or over night. Recombinant protein loading was confirmed by SYPRO Ruby 
protein Blot Staining (Life Technologies).  
For mass spectrometry, recombinant kinase dead AMPK trimmers (α2β2γ1) were 
used as a substrate for CDK4/CyCD3. Recombinant kinase dead AMPK trimers 
(α2β2γ1) were produced by the DG. Hardie lab.  
Mitochondrial isolation 
Quadriceps muscle from Cdk4+/+ or Cdk4-/- mice were homogenized in 2ml cold 
buffer I. Tissue homogenization was obtained at 1500rpm after 30 strokes. The 
homogenized extract was then centrifuged at 600g for 10 min at 4°C in order to 
remove cellular debris. This step was performed three times. The mitochondrial 
fraction was pelleted at 10000g for 10 min at 4°C and subsequently washed using 
buffer II. The mitochondrial pellet was suspended in 80ul cold buffer II.  
Mitochondria were immediately used for seahorse analysis.  Buffers I composition 
is as follows: 210 mM mannitol, 70 mM sucrose, 5 mM HEPES, 1 mM EGTA, 0.5% 
BSA pH to 7.4. Buffer II composition is as follows :  210 mM mannitol, 70 mM 
sucrose, 10 mM MgCl2, 5 mMK2HPO4, 10 mM MOPS, 1 mM EGTA pH to 7.4.  
 
Isolation of adult skeletal muscle fibers 
 
Flexor digitorum brevis (FDB) muscles were incubated for 45 min at 37°C in an 
oxygenated ‘Krebs-Hepes’ solution containing 0.2% collagenase type IV (Gibco). 
Muscles were then washed twice in DMEM/F12 supplemented with 2% fetal 
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bovine serum and mechanically dissociated by repeated passages through ﬁre-
polished Pasteur pipettes of progressively decreasing diameter. Dissociated ﬁbers 
were plated directed onto Seahorse XF24 tissue culture dishes coated with 
Matrigel and allowed to adhere to the bottom of the dish for 2h. After checking the 
adhesion of the fibers, a seahorse Fatty acid oxidation was performed as described  
The Krebs-Hepes solution contains NaCl 135.5mM, MgCl2 1.2mM, KCl 5.9mM, 
glucose 11.5mM, Hepes 11.5mM and CaCl2 mM. 
 
Seahorse analyses 
For seahorse analysis, the cells were seeded 16 hours before the experiment.  
Mitochondrial function was determined with an XF-24 extracellular flux analyzer 
(Seahorse Bioscience). Oxygen consumption Rate (OCR) and Extracellular 
acidification rate (ECAR) was measured in adherent MEFs. Control and mutant 
fibroblast cells were seeded in an XF 24-well cell culture microplate at a density of 
7×105 cells per cell in 200 μL DMEM/F12 media. Cells were incubated for 16 h at 
37 °C in 5% CO2 before the assay. OCR was expressed as pmol of O2 per minute and 
was normalized by protein content a Pierce BCA Protein Assay protocol (Thermo 
Fisher Scientific).  ECAR was expressed as mpH per minute and was normalized by 
protein content a Pierce BCA Protein Assay protocol (Thermo Fisher Scientific).  
For glycolysis experiments, just before the experiment the cells were washed, 
and the growth medium was replaced with DMEM medium containing only 2mM 
Glutamine. Cells were then pre-incubated for 1 h at 37 °C without CO2 to allow cells 
to pre-equilibrate with the assay media before starting the glycolysis test 
procedure. After measuring baseline ECAR, ECAR was measured after an acute 
injection of 25mM Glucose. The glycolytic rate was calculated as glucose 
dependent ECAR. It was calculated as follows: Glucose induced ECAR-basal ECAR.  
For fatty acid oxidation experiments, just before the experiment the cells are 
washed, and the growth medium was replaced with KHB containing 2.5mM 
Glucose and 1.5mM of carnitine. Cells were then pre-incubated for 1 h at 37 °C 
without CO2 to allow cells to pre-equilibrate with the assay media before starting 
the fatty acid oxidation procedure. After measuring baseline OCR as an indication 
of basal respiration, OCR was measured after an acute injection of 400µM or 
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150µM of palmitate coupled to BSA (for MEFs and myotubes respectively).  
For FDB muscle fibers 125µM of palmitate coupled to BSA, 400nM of FCCP and 
1µM of Antimycine A were injected directly onto the fibers using the seahorse 
analyzer. Fatty acid oxidation was induced by the palmitate injection. The 
uncoupling agent FCCP induced the maximal respiration.  
OCR was expressed as pmol of O2 per minute and was normalized by total DNA 
content.  
For mitochondrial respiration, 50 μl of mitochondrial suspension (containing 
10µg of freshly isolated mitochondria) were used per well. The XF24 cell culture 
microplate was centrifuged at 2000g for 20 minutes at 4 °C.   The assay medium 
contained 250 mM sucrose, 15 mM KCl, 1 mM EGTA, 5 mMMgCl2, 30 mM K2HPO4, 
2mM Hepes and 0.2% FFA-Free BSA. 0.5mM Malate, 80µM PalmitoylCoA, 240µM 
Carnitine and 4mM ADP  diluted in assay medium were added after the 
centrifugation of the mitochondria to obtain a final volume of 525µl per well.  After  
10 min of incubation at 37°C without CO2 the mitochondrial respiration was 
measured using the seahorse analyzer.   
 
Immunopreciptation 
Myotubes or liquid N2 grinded muscle samples were lysed in M-PER™ buffer 
(Thermofisher Scientific) and incubated in agitation for one hour at 4°C. 2-5 mg of 
protein was inmunoprecipitated overnight with an AMPKα2 antibody (Santa Cruz, 
sc-19131) and Protein G coupled with magnetic beads (Sigma, 1004D) in the 
following buffer (IP buffer): 25 mM TRIS pH 7.9, 5 mM MgCl2, 10% Glycerol, 100 
mM KCl, 0.1% NP40, 0.3 mM DTT. Next day, beads were washed for times with the 
IP buffer and frozen. Samples were used for mass spectrometry.    
 
Mass spectrometry 
In the in vitro assays, protein samples were loaded on a 12 % mini polyacrylamide 
gel and migrated about 3 cm, while in the immunoprecipitation experiments 
proteins were loaded on an 8% gel and fully migrated. After Coomassie staining, 
visible band between 50 and 75 kDa corresponding to AAPK2 was excised and 
digested with sequencing-grade trypsin (Promega). Extracted tryptic peptides 
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were dried and resuspended in 0.05% trifluoroacetic acid, 2% (v/v) acetonitrile 
for mass spectrometry analyses. 
Tryptic peptide mixtures were injected on an Ultimate RSLC 3000 nanoHPLC 
system (Dionex, Sunnyvale, CA, USA) interfaced via a nanospray source to a high 
resolution mass spectrometer based on Orbitrap technology: Fusion Tribrid or 
QExactive Plus  (Thermo Fisher, Bremen, Germany), depending on the experiments 
considered. Peptides were loaded onto a trapping microcolumn Acclaim 
PepMap100 C18 (20 mm x 100 μm ID, 5 μm, Dionex) before separation on a C18 
reversed-phase analytical nanocolumn at a flowrate of 0.25 μl/min, using a 
gradient from 4 to 76 % acetonitrile in 0.1 % formic acid (total time: 65min).  
The in vitro experiments were analysed with a Fusion mass spectrometer 
interfaced to a custom packed 40-cm C18 column (75 μm ID, 100Å, Reprosil Pur 
1.9 um particles). Full MS survey scans were performed at 120’000 resolution. 
Data-dependent acquisition was controlled by Xcalibur 3.0 software (Thermo 
Fisher) and applied a top speed precursor selection strategy to maximize 
acquisition of peptide tandem MS spectra with a maximum cycle time of 3s. 
Multiple-charge precursor ions were isolated in the quadrupole with a window of 
1.6 m/z width and then dynamically excluded from further selection during 60s. 
HCD fragmentation was performed in the ion routing multipole with 32% 
normalized collision energy and fragment ions were measured in the ion trap. 
The immunoprecipitation experiments were analysed with a Q-Exactive Plus 
instrument interfaced to an Easy Spray C18 PepMap column (50cm x 75µm ID, 
2µm, 100Å, Dionex). Full MS survey scans were performed at 70’000 resolution. In 
data-dependent acquisition controlled by Xcalibur 3.1 software (Thermo Fisher), 
the 10 most intense multiple-charge precursor ions detected in the full MS survey 
scan were selected for higher energy collision-induced dissociation (HCD, 
normalized collision energy NCE=27 %) and analysis in the orbitrap at 17’500 
resolution. The window for precursor isolation was of 1.5 m/z units around the 
precursor and selected fragments were excluded for 60s from further analysis. 
MS data were analysed using Mascot 2.6 (Matrix Science, London, UK) set up to 
search the UniProt database (www.uniprot.org) restricted to Homo sapiens  (in 
vitro experiments) or Mus musculus (immunoprecipitation experiments) taxonomy 
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(SwissProt, November 2016 version: 20’130 and 16’846 sequences, respectively). 
Trypsin (cleavage at K,R) was used as the enzyme definition, allowing 3 missed 
cleavages. Mascot was searched with a parent ion tolerance of 10 ppm and a 
fragment ion mass tolerance of 0.5 (Fusion MS data) or 0.02 Da (QExactive MS 
data). Iodoacetamide derivative of cysteine was specified in Mascot as a fixed 
modification. N-terminal acetylation of protein, oxidation of methionine, and 
phosphorylation of serine, threonine or tyrosine were specified as variable 
modifications. 
Scaffold software (version 4.7.5, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications, and to perform dataset 
alignment. Peptide identifications were accepted if they could be established at 
greater than 90.0% probability by the Scaffold Local FDR algorithm. Protein 
identifications were accepted if they could be established at greater than 95.0% 
probability and contained at least 2 identified peptides. Protein probabilities were 
assigned by the Protein Prophet algorithm. Proteins that contained similar 
peptides and could not be differentiated based on MS/MS analysis alone were 
grouped to satisfy the principles of parsimony. Proteins sharing significant peptide 
evidence were grouped into clusters. 
MsViz software (Martin Campos et al., 2017) was used to compare sequence 
coverage and phosphorylation of the AMPK alpha 2 protein in the in vitro 
experiments. 
HPLC  
Cells were grown in 10 cm dishes and treated as indicated in the figure legends. 
Culture medium was removed by aspiration, rinsed with ultra pure water, flash 
frozen with liquid nitrogen, thawed on ice, and followed by immediate addition of 
ice-cold 0.4M perchloric acid (500 µl). Cells were scrapped off thoroughly, and 
transferred to 1.5-ml microfuge eppendorf tubes. Samples were incubated at 4°C 
for 45 minutes, and centrifuged at 14,000 rpm at 4C for 10 minutes. The 
supernatant (500 µl) was collected, mixed with 500µl K2CO3 4M, and incubated at 
least 1h at -80°C. The samples were again centrifugated at 4C for 10 minutes, the 
supernatant collected and tested on HPLC. 
External standards stocks were prepared in ultra pure water, at 10 mg/ml, and 
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treated in exactly the same way as the samples. 
For normalization, protein measurements were performed using a Pierce BCA 
Protein Assay protocol (Thermo Fisher Scientific). In parallel DNA was extracted 
from the pellets and quantified.  
The gradient elution was performed as described (Manfredi et al., 2002) on a 4.6-
mmi.d, 150-mm, Kinetex 5u EVO C18 100A HPLC column (Phenomenex) with two 
buffers at a rate of 0.5 ml/min. Buffer A contained 25mM NaH2PO4, 100 mg/liter 
tetrabutylammonium hydrogen sulfate, pH 5. Organic buffer B was composed of 
10% (v/v) acetonitrile in 200mM NaH2PO4, 100 mg/liter tetrabutylammonium 
hydrogen sulfate, pH 4.0. Buffers were filtered and degassed. The gradient was 
100% buffer A from 0–5 min, 100% buffer A to 100% buffer B from 5–20 min, and 
100% buffer A from 20 to 31 min for column reequilibration, which was sufficient 
to achieve stable baseline conditions. 25 microliters of prepared sample was 
autoinjected and UV monitored at 260nm from 0 to 31 min for phosphorylated 
nucleotides. Peaks were identified by their retention times and by using co-
chromatography with standards. 
Each standard of interest was first subjected to chromatography 
individually to obtain its retention time (Manfredi et al., 2002) and to be able to 
later identify each compound in a standard mixture. A standard curve for each 
compound was constructed by plotting peakheight s (lV) versus concentration. 
Linear curves were obtained with R2 values > 0.95. The quantification of 
nucleotides in the sample was performed using the external standard calibration, 
integrating sample peak heights against corresponding standard curves. 
mRNA analysis.  
Muscle tissues were grinded to powder in liquid nitrogen. mRNAs from muscle 
was isolated using TRIREAGENT according to the manufacturer’s protocol. One 
microgram of the RNA was subsequently reverse-transcribed  (Superscript II, Life 
Technologies) and quantified via real-time quantitative PCR using an ABI 7900HT 
instrument. qPCR analysis was performed using a 7900HT Fast Real-Time PCR 
System (Applied Biosystems) and SYBR Green detection of the amplified products. 
The relative quantification for a given gene was corrected to RS9 mRNA values 
(oligonucleotide sequences are provided in Table 3).  
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QUANTIFICATION AND STATISTICAL ANALYSIS 
The results were expressed as means ± standard error of the means (s.e.m). 
Comparisons between 2 groups were performed with an unpaired 2-tailed 
Student’s t test and multiple group comparisons were performed by unpaired 1-
way ANOVA followed by Tukey’s test and 2-way ANOVA, followed by Tukey’s test. 
All p-values below 0.05 were considered significant. Statistical significance values 
were represented by asterisks corresponding to *p<0.05,  **p<0.001,  
***p<0.001and ****p<0.0001.   
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